Disease · MONDO_0018479
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| DB Period: Crinecerfont vs DB Period: Placebo: deaths from any cause | 0 of 122 | 0 of 60 | 182 | NCT04490915 | Trial comparisons |
| DB Period: Crinecerfont vs DB Period: Placebo: serious adverse events | 4 of 122 | 0 of 59 | 181 | NCT04490915 | Trial comparisons |
| Relacorilant vs Placebo: Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0. | 67 of 68 | 60 of 69 | 137 | NCT04308590 | Trial comparisons |
| Relacorilant vs Placebo: deaths from any cause | 1 of 68 | 0 of 69 | 137 | NCT04308590 | Trial comparisons |
| Relacorilant vs Placebo: serious adverse events | 15 of 68 | 4 of 69 | 137 | NCT04308590 | Trial comparisons |
| Chronocort® vs Standard Glucocorticoid Therapy: deaths from any cause | 0 of 61 | 0 of 61 | 122 | NCT02716818 | Trial comparisons |
| Chronocort® vs Standard Glucocorticoid Therapy: serious adverse events | 7 of 61 | 5 of 61 | 122 | NCT02716818 | Trial comparisons |
| DB Period: Crinecerfont vs DB Period: Placebo: deaths from any cause | 0 of 69 | 0 of 34 | 103 | NCT04806451 | Trial comparisons |
| DB Period: Crinecerfont vs DB Period: Placebo: serious adverse events | 1 of 69 | 4 of 33 | 102 | NCT04806451 | Trial comparisons |
| Tildacerfont Group vs Placebo: Effect of Tildacrfont in Reducing GC Use to Near-physiologic Levels While Maintaining Androgen Control in Subjects With CAH | 4 of 48 | 5 of 52 | 100 | NCT04544410 | Trial comparisons |
| Tildacerfont Group vs Placebo: Effectiveness in Reducing Cardiovascular Risk in Subjects With CAH | 26 of 48 | 19 of 50 | 98 | NCT04544410 | Trial comparisons |
| Relacorilant vs Placebo: Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg | 10 of 42 | 13 of 42 | 84 | NCT04308590 | Trial comparisons |
| Relacorilant vs Placebo: Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg) | 9 of 42 | 13 of 42 | 84 | NCT04308590 | Trial comparisons |
| Investigational Therapy vs Standard Therapy: deaths from any cause | 0 of 31 | 0 of 35 | 66 | NCT00001521 | Trial comparisons |
| Investigational Therapy vs Standard Therapy: serious adverse events | 3 of 31 | 10 of 35 | 66 | NCT00001521 | Trial comparisons |
| Relacorilant vs Placebo: Number of Patients With Any Dose Decrease in Antihypertensive Medication | 7 of 22 | 5 of 33 | 55 | NCT04308590 | Trial comparisons |
| Relacorilant vs Placebo: Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL | 1 of 27 | 0 of 28 | 55 | NCT04308590 | Trial comparisons |
| Relacorilant vs Placebo: Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication | 1 of 22 | 5 of 33 | 55 | NCT04308590 | Trial comparisons |
| Investigational Therapy vs Standard Therapy: Number of Participants With Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) > 2.5 | 8 of 18 | 12 of 26 | 44 | NCT00001521 | Trial comparisons |
| Tildacerfont Group vs Placebo: Effect of Tildacrfont in Reducing GC Use to Near-physiologic Levels While Maintaining Androgen Control in Subjects With CAH | 2 of 19 | 4 of 25 | 44 | NCT04544410 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018479/comparisons